Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Parallel-group, Dose Escalation Placebo-controlled Multicenter Study to Investigate the Safety and Tolerability of IBP-9414 Administered in Preterm Infants.

NCT02472769 is registered in ClinicalTrials.gov with Infant Bacterial Therapeutics as lead sponsor.

NCT NCT02472769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02472769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Parallel-group, Dose Escalation Placebo-controlled Multicenter Study to Investigate the Safety and Tolerability of IBP-9414 Administered in Preterm Infants.
Lead sponsor
Infant Bacterial Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
May 27, 2016
Completion date
August 7, 2017
Enrollment
120 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

necrotizing enterocolitis